Feb 08,2022

Abbott Announces Partnerships with 1MG, PharmEeasy and 7 Other in India

Abbott, a global healthcare leader, has partnered with key health-tech firms including BeatO, Sugar.fit, PharmEasy, GOQii, 1MG, Zyla Health, Healthifyme and Fitterfly to usher in a new era of holistic diabetes management care. Through these collaborations, Abbott aims to offer glucose monitoring solutions to 8 million people living with diabetes, of which approximately 6.5 million users can access through PharmEasy and 1MG. The company is focused on maintaining effective glucose level along with remote consultations, diabetes-specific coaching, and dietary plans.
 

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 10,2022

Abbott reinforces its commitment towards access to holistic diabetes care

Abbott announced new collaborations with key health-tech partners BeatO, Sugar.fit, PharmEasy, GOQii, 1MG, Zyla Health, Healthifyme and Fitterfly to usher in a new era of holistic diabetes management care. Through these collaborations, Abbott aims to offer glucose monitoring solutions to 8 million people living with diabetes, of which approximately 6.5mn users can access through PharmEasy and 1MG. The company focuses on maintaining effective glucose levels and remote consultations, diabetes-specific coaching, and dietary plans. 

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
May 04,2022

Carbon Health Technology: Continuous Glucose Monitoring with Abbott and Dexcom

The Steady Health team joined Carbon Health in 2021, and since then the company has been working tirelessly together to bring the Carbon Health vision of omnichannel, continuous, sensor-driven care for chronic conditions like diabetes to life. To this end, Carbon Health partners with Abbott and Dexcom for deeply natively integrated continuous glucose monitoring.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 20,2017

One Drop Among First Apps to Integrate Dexcom CGM Data

In case you just so happen to have missed this nugget of news gold, Dexcom opened up their API to the masses — and One Drop was there to snag a spot. In more technical terms: The CGM powerhouse took their API public, enabling third-party developers to pull Dexcom CGM data directly into their apps.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 06,2023

Fitterfly presents outcomes from Digital Therapeutics Platform at 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023), Germany

Fitterfly's first presentation focused on how their Digital Therapeutics solutions were able to benefit the participants through use of CGM-led behavior change, and personalized lifestyle changes during the 90-day program. Study data included 145 patients who were put on a CGM device for 14 days and then received personalised coaching based on their glycemic responses for next 11 weeks. The study showed 10% improvement in Time in Range (from 66% to 72%) within 14 days and 1% reduction in HbA1c from a baseline of 8.1% in 3 months. This was also accompanied by an average of 2.3 kg of weight loss.

CLINICAL STUDY

#cgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 02,2023

Expanded Medicare coverage for CGM to go into effect next month

The Centers for Medicare & Medicaid Services today published a final local coverage determination (LCD) expanding coverage for continuous glucose monitors (CGMs). New, expanded coverage of CGMs under Medicare go into effect in April. CMS first published the local coverage determination (LCD) modifying coverage criteria for CGMs in October. The modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia. The proposal eliminates the requirement for frequent adjustments of the patient’s insulin treatment regimen. The finalized version changed some language on the criteria. It amended the line saying “the beneficiary is insulin-treated with at least one daily administration of insulin” to, simply, “the beneficiary is insulin-treated.” According to BTIG analyst Marie Thibault, the decision increases access for approximately 1.5 million people using basal-only treatment in the U.S. covered by Medicare. That could expand to between 3 million and 4 million, she said, as U.S. commercial payors follow suit.

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 03,2023

France Diabetes Market Report 2023: Type 2 Diabetes is Expected to Grow Year on Year, Fueling Demand for Treatment

France Diabetes Market will reach US$ 3.39 Billion in 2028 and expand at a CAGR of 2.75% from 2023 to 2028, according to the publisher. France's statutory health insurance (SHI) covers 100% of it, and the number of covered patients has doubled in the past ten years. Nearly a million are diagnosed with diabetes in France, according to the World Health Organisation (WHO). There is an increasing demand for diabetes monitoring devices due to favourable reimbursement policies, a large population of patients with insulin-dependent diabetes, and the introduction of new products by industry players.

#bgm

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 06,2023 TOP STORY

U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems

Abbott today announced that the U.S. Food and Drug Administration has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring system sensors for integration with automated insulin delivery (AID) systems. Abbott modified the sensors to enable integration with AID systems. AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors. The company is partnering with Insulet and Tandem for future integrations in multiple countries, including the U.S. Outside the U.S., Abbott's FreeStyle Libre 3 sensor is already authorized to work with the mylife™ Loop solution from Ypsomed and CamDiab in Germany, with additional launches in the UK, Switzerland and the Netherlands planned for the first half of this year.

REGULATORY FDA

#cgm

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 06,2023 TOP STORY

Bigfoot Biomedical takes next steps for its holistic diabetes management platform

Less than two years ago, Bigfoot Biomedical launched its Bigfoot Unity platform in some U.S. states. Just last month, the company made a major play to further bolster this platform. It sold pump-based automated insulin delivery technology patents to pump maker Insulet for $25 million. Further positives followed within weeks, as Bigfoot soon after received FDA clearance for the Android mobile app for Bigfoot Unity. CEO Jeffrey Brewer explained that a “substantial amount” of Bigfoot Biomedical’s early work came on a closed-loop automated insulin delivery (AID) system. However, Bigfoot concluded that it couldn’t carry on with both the AID technology and the Bigfoot Unity platform. Brewer said the next steps for Bigfoot are to take the limited commercial launch to a larger population of people. Currently, the Bigfoot Unity works with the Abbott FreeStyle Libre 2 CGM. With the next-generation FreeStyle Libre 3 receiving FDA clearance last year, Brewer said Bigfoot plans to extend compatibility with future versions when ready.

#cgm

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 01,2023

Canada Diabetes Industry Report to 2028

Canada's Diabetes Market will reach US$ 1.53 Billion by 2028 with a CAGR of 3.85% during the forecast period (2023-2028), according to the publisher.

#cgm

#bgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM